

Menopausal Hormone Therapy

Clinicopathologic benefits, adverse effects, and individualized risk

Estrogen withdrawal and symptom burden

Evidence from the Women's Health Initiative

Breast, endometrial, vascular, and skeletal consequences

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)


www.abusuraihsakhri.com

Learning outcomes

- Explain the symptomatic and tissue effects of declining estrogen at menopause.
- Distinguish combined estrogen–progestin therapy from estrogen-only therapy.
- Interpret the main benefits and adverse outcomes reported in the Women’s Health Initiative.
- Explain why age, timing, duration, regimen, and route modify risk.
- Apply the source evidence to brief clinical risk–benefit scenarios.

The central clinical problem

CONCEPTUAL SEQUENCE



Schematic — simplified teaching model

Menopause: The initiating endocrine change

- Circulating estrogen levels decline as females approach menopause.
- Symptoms may involve thermoregulation and the lower genitourinary tract.
- Long-term estrogen deficiency is associated with skeletal and other health effects.
- The clinical challenge is to relieve symptoms without creating avoidable treatment-related harm.

Symptom domains of estrogen withdrawal

Vasomotor

- Hot flashes
- Night sweats
- Symptoms prompting consideration of MHT

Genitourinary

- Vaginal dryness
- Urinary urgency and frequency
- Recurrent urinary tract infections

Vasomotor symptoms: The original treatment target

- Hot flashes and night sweats are prominent menopausal complaints.
- Relief of these symptoms was an early rationale for systemic hormone therapy.
- The presence of symptoms does not establish that systemic therapy is suitable for every patient.
- Safety decisions must separately account for cancer and vascular risks.

Genitourinary symptoms have a distinct profile

- Vaginal dryness can coexist with urinary urgency and frequency.
- Recurrent urinary-tract infections are included among the menopausal-associated symptoms.
- Symptom domain matters when evaluating therapeutic goals.
- Systemic MHT risk; It does not provide a detailed local-treatment algorithm in this section.

Consequences linked to estrogen deficiency


Domain	Robbins-described association	Teaching interpretation
Bone	Increased osteoporosis risk	Bone preservation is a potential MHT benefit.
Cardiovascular	Higher cardiovascular disease risk	Association does not prove that MHT prevents events.
Cognition	Cognitive decline in aging females	MHT is not recommended to prevent dementia.
Symptoms	Vasomotor and genitourinary symptoms	Symptom control is the primary clinical indication discussed.

What menopausal hormone therapy means

- MHT administers exogenous hormonal agents to address menopausal symptoms.
- Older terminology: Hormone replacement therapy.
- The most common systemic regimen combines an estrogen with progesterone or a synthetic progestin.
- Estrogen-only therapy is described for females who have undergone hysterectomy.

Why a progestogen is added

CONCEPTUAL SEQUENCE



Schematic — simplified teaching model

Treatment choice begins with uterine status

Uterus present

- Estrogen exposure raises a uterine cancer concern.
- The common regimen contains estrogen and a progestogen.
- Endometrial risk must remain part of monitoring and counseling.

After hysterectomy

- The uterine cancer rationale for a progestogen no longer applies.
- Estrogen alone in this group.
- Other risks still need assessment.


Unopposed estrogen: A pathologic mechanism

- Prolonged estrogenic stimulation favors glandular proliferation in the endometrium.
- Exogenous estrogen is among the associations of endometrial hyperplasia.
- Hyperplasia is an important cause of abnormal uterine bleeding.
- Some hyperplastic lesions are precursors to endometrioid endometrial carcinoma.


Endometrial proliferation: Conceptual morphology

SCHEMATIC — NOT A HISTOLOGIC SPECIMEN

Less crowded glandular arrangement



Hyperplasia: Crowding of glands



Purpose: Illustrate relative gland crowding, not diagnose atypia

Two hyperplasia morphologies

Without atypia


- Increased gland-to-stroma ratio
- Variable gland size and shape
- Stroma generally remains between glands

Atypical hyperplasia / EIN

- Complex crowded glands
- Nuclear atypia is present
- Substantial morphologic overlap with low-grade carcinoma

Endometrial risk is biologically plausible

CONCEPTUAL SEQUENCE



Schematic — source-based conceptual sequence

Keep prevention distinct from symptom treatment


- Relief of menopausal symptoms is different from preventing long-term disease.
- Early MHT use was also promoted for bone, coronary, and cognitive outcomes.
- Those presumed preventive advantages required testing in prospective trials.
- Robbins does not recommend MHT for cardiovascular disease or dementia prevention.

Before the Women's Health Initiative

- Initial clinical studies suggested slower postmenopausal bone loss.
- Other early reports suggested fewer myocardial infarctions.
- A reduction in cognitive decline was also proposed.
- These beliefs helped broaden MHT use beyond immediate symptoms.

Evidence forced reassessment

CONCEPTUAL SEQUENCE



Schematic — source-based conceptual sequence

WHI: What was studied

- The initial WHI findings were published in 2002.
- The cited trial was large, prospective, and placebo controlled.
- Approximately 17,000 participants were studied.
- The examined regimen combined conjugated equine estrogens with medroxyprogesterone acetate.

WHI inference: Specify the exposure

- The trial result concerns a particular estrogen–progestin formulation.
- It should not be silently equated with every dose, route, and hormonal preparation.
- Age at initiation and baseline risk may also change treatment effects.
- Robbins explicitly emphasizes this heterogeneity when reappraising MHT.

WHI reported fewer fractures

Skeletal protection was observed

MHT reduced fractures among participants receiving therapy.

This positive finding coexisted with significant adverse outcomes.

A fracture benefit alone cannot establish a favorable overall risk–benefit balance.

WHI identified increased breast cancer risk

Combination therapy carried a cancer signal

Breast cancer risk increased during combination MHT.

The increase after a median exposure of 5–6 years.

Therapy duration therefore matters when interpreting risk.

WHI identified increased stroke risk

Vascular outcomes altered the benefit–risk assessment

The combination-therapy trial reported more strokes.

Later analyses emphasize risk differences by age and treatment route.

A possible subgroup benefit does not negate this adverse-event signal.

WHI identified increased VTE risk

Venous thrombosis is a major safety domain

Combination therapy increased venous thromboembolism.

Deep vein thrombosis and pulmonary embolism are included.

Risk is higher in patients with additional prothrombotic factors.

WHI coronary finding was not preventive

No reduction in coronary heart disease incidence

The original combination-therapy trial did not lower CHD incidence.

Later analyses suggest age and timing modify cardiovascular effects.


MHT is not recommended as primary prevention of cardiovascular disease.

The initial WHI outcome pattern

Outcome	Reported effect of combined therapy	Interpretive consequence
Fractures	Reduced	A demonstrable skeletal benefit
Breast cancer	Increased	Relevant to longer use
Stroke	Increased	Major vascular harm
Venous thromboembolism	Increased	Assess thrombosis risk
Coronary heart disease	No reduction in incidence	Not a coronary prevention strategy

Practice changed after WHI

TREATMENT USE (%)




A decline in MHT use from 22% to 4.7% by 2010. The first percentage is not assigned an exact calendar year in the text.

Declining MHT use and breast cancer diagnoses

- The sharp decrease in MHT use was accompanied by an apparent decline in newly diagnosed breast cancers.
- Robbins also notes changed screening patterns in older females.
- Concurrent trends support a hypothesis but do not alone prove an individual-level causal effect.
- The prospective WHI findings provide stronger evidence for the treatment-related signal.

Modern interpretation: Five effect modifiers

CONCEPTUAL SEQUENCE



Schematic — source-based conceptual sequence

Combined and estrogen-only regimens

Estrogen + progestogen

- Used with an intact uterus
- WHI combined-therapy breast cancer signal
- Results cannot automatically represent estrogen-alone therapy

Estrogen alone

- Used after hysterectomy
- Different risk profile may apply
- Requires separate assessment of vascular and other effects

Why duration must be explicit

- Breast cancer risk with combined therapy is described after a median 5–6 years.
- Venous thrombosis risk appears especially pronounced in the first 2 years.
- Different harms therefore have different time courses.
- A single duration label cannot summarize all organ-specific risks.

Do not confuse cancer endpoints

Organ	What Robbins states	What cannot be inferred
Breast	Combined MHT increases risk after median 5–6 years.	All hormone regimens have identical risk.
Ovary	No increased ovarian cancer risk in this MHT summary.	The treatment prevents ovarian cancer.
Uterus	Unopposed estrogen raises uterine cancer concern.	A hysterectomy removes systemic vascular risks.

Breast cancer risk: A clinicopathologic reading

- Exogenous hormonal therapy is listed among breast cancer risk factors.
- Population incidence shifts can be affected by changes in mammographic screening.
- The combination-therapy trial establishes an adverse signal under its studied exposure.
- Avoid treating one relative-risk association as a personalized absolute prediction.

Early and later initiation differ

Initiated below age 60


- MHT may have favorable effects on atherosclerosis and coronary disease.
- Baseline risk and healthy endothelium appear important.
- Not a recommendation for preventive MHT.

Initiated after age 60

- Greater CHD risk.
- Stroke and VTE risk are also increased.
- An older age at initiation changes the balance.

The cardiovascular timing hypothesis

CONCEPTUAL SEQUENCE



Schematic — simplified teaching model

Healthy vascular endothelium matters

- Potential benefit in younger women partly to endothelial estrogen-receptor responses.
- Age at treatment initiation is therefore more than an administrative variable.
- Atherosclerosis and pre-existing vascular risk may alter the response to the same hormone exposure.
- The timing hypothesis remains distinct from proof of clinical prevention.

Cardiovascular prevention is not an indication

A favorable subgroup hypothesis is not clinical prophylaxis

Initial WHI did not show fewer CHD events with combination therapy.

Later analyses identify age-related effect modification.


Robbins explicitly advises against MHT to prevent cardiovascular disease.

Venous thromboembolism: Clinical meaning

- VTE encompasses deep venous thrombosis and pulmonary embolism.
- MHT-associated excess thrombosis may have severe consequences.
- Risk is greater when estrogen exposure coexists with other prothrombotic conditions.
- Assessment must examine both medication and host factors.

Two-hit model of VTE susceptibility

CONCEPTUAL SEQUENCE



Schematic — simplified teaching model

VTE is especially important early in treatment

- The MHT-associated increase is more pronounced in the first 2 years.
- An early uneventful interval does not establish long-term freedom from risk.
- Timing of therapy and duration should both be documented.
- Risk review should precede treatment initiation.

Factor V Leiden as a risk modifier


- Factor V Leiden is an inherited predisposition to venous thrombosis.
- Its mechanism involves resistance to inactivation by activated protein C.
- It as a MHT risk-enhancing hypercoagulable state.
- A genetic predisposition may interact with acquired exposures.

Prothrombin G20210A is another modifier

- The prothrombin gene variant is associated with increased prothrombin levels.
- Prothrombin mutations among MHT-related hypercoagulable risk conditions.
- Risk is not binary: Thrombophilic traits may coexist with immobility and treatment exposure.
- Do not infer that all carriers develop thrombosis.

Immobilization and MHT can interact

CONCEPTUAL SEQUENCE



Schematic — source-based conceptual sequence

Keep venous and arterial outcomes separate

Venous thrombosis


- DVT and pulmonary embolism
- Strong interaction with thrombophilia and immobility
- Risk appears especially pronounced early

Stroke / coronary events

- Arterial clinical endpoints
- Affected by age and vascular disease status
- Do not infer identical mechanisms or risk size

Why administration route is relevant

CONCEPTUAL SEQUENCE



Schematic — simplified teaching model

Oral versus transdermal estrogen

Oral route

- Passes through the liver first
- First-pass metabolism can raise triglyceride levels
- VTE/stroke risk appears relatively higher

Transdermal route

- Avoids hepatic first-pass exposure
- Appears to carry lower VTE/stroke risk
- May be preferred with obesity or high triglycerides

Route differences are not guarantees


- The source uses qualified wording: VTE and stroke risks “appear” lower with transdermal estrogen.
- Avoid translating this into “no vascular risk.”
- Dose, formulation, age, and background risk remain relevant.
- The clinical comparison is qualitative in the supplied section.

Obesity and high triglycerides change route choice

- Obesity and high triglyceride levels as reasons transdermal therapy may be preferred.
- First-pass hepatic metabolism is an important rationale for route-dependent effects.
- These features are considered alongside pre-existing thrombosis risk.
- They should not be reduced to a single universal treatment rule.

Estrogen helps preserve skeletal mass


CONCEPTUAL SEQUENCE



Schematic — simplified teaching model

Estrogen deficiency increases bone turnover

CONCEPTUAL SEQUENCE



Schematic — source-based conceptual sequence


Why postmenopausal osteoporosis develops

- Bone formation and bone resorption both increase with estrogen deficiency.
- Resorption dominates, producing high-turnover osteoporosis.
- The cancellous compartment of vertebral bodies is particularly affected.
- Loss of trabecular connectivity explains mechanical fragility.

Trabecular connectivity determines strength

SCHEMATIC — NOT A MICROGRAPH OR QUANTITATIVE MEASURE

Connected trabecular framework



Postmenopausal bone loss



Progressive thinning and disconnection increase fragility

Osteoporosis: The pathology is loss of bone quantity

- Histologically normal bone is present in reduced quantity.
- Trabecular plates become thin and can lose interconnections.
- Microfractures and vertebral collapse may follow.
- The phenomenon is not a mineralization disorder such as osteomalacia.

Skeletal consequences have clinical weight

- Vertebral fractures may cause pain, reduced height, and spinal deformity.
- Hip, pelvic, and spinal fractures can produce prolonged immobility.
- Immobilization itself can lead to serious complications.
- WHI fracture reduction therefore represents a clinically meaningful treatment effect.

Bone assessment is a separate clinical task

- Plain radiographs are insensitive until substantial bone mass is lost.
- Dual-energy x-ray absorptiometry measures bone mineral density.
- Normal serum calcium does not exclude osteoporosis.
- Fracture risk cannot be evaluated from menopausal symptoms alone.

Other approaches to bone preservation

Intervention category	Examples described by Robbins	Relation to MHT
Activity and nutrition	Exercise; adequate calcium and vitamin D	Support skeletal health independent of MHT.
Antiresorptive medication	Bisphosphonates	Nonhormonal fracture-prevention options.
Targeted antiresorptive	Denosumab (anti-RANKL)	Addresses osteoclast signaling.
MHT	Estrogen agonist treatment	Bone benefit constrained by vascular hazards.

MHT for osteoporosis requires selective judgment

Bone benefit does not erase systemic harm

Robbins recognizes fracture reduction and slowed bone loss.

Deep vein thrombosis and stroke limit estrogen use for bone treatment.


MHT may be appropriate for prevention of osteoporosis in selected females.

A practical risk–benefit matrix

Variable	Potentially favorable context	Cautionary context
Symptoms	Bothersome menopausal symptoms	No symptomatic indication
Age / timing	Below 60; within 10 years of menopause	Initiation after 60
Thrombosis	No recognized major thrombotic risk	VTE risk, thrombophilia, immobilization
Route	Transdermal may fit selected risk profiles	Assuming all routes are equivalent
Goal	Symptom treatment; selected bone prevention	CVD or dementia prophylaxis

Clinical decision sequence

CONCEPTUAL SEQUENCE



Schematic — simplified teaching model

The early symptomatic patient

- Robbins supports a role for systemic agents in early symptomatic menopause.
- The described favorable context includes age below 60 years and less than 10 years since menopause.
- The patient should lack major contraindicating vascular risk factors.
- A decision remains individualized rather than automatic.

Why later initiation is different

- Increased CHD risk when therapy begins after age 60.
- Stroke and VTE risks are also increased with later initiation.
- The timing hypothesis discourages projecting young-cohort findings onto older patients.
- Initiating MHT solely to prevent chronic disease is not supported.

Treatment duration: The source recommendation

- An initial treatment period followed by reassessment.
- Its stated consensus is to taper oral agents at 3–5 years.
- This is a textbook summary, not a substitute for a current individualized clinical guideline.
- The duration of exposure should be recorded alongside the reason for continuing therapy.

When symptoms persist

- A possible move to transdermal therapy if symptoms persist after oral treatment.
- Route change may address some, but not all, risk concerns.
- Review the original indication, age, and intervening vascular risk factors.
- Do not equate symptom persistence with an absence of treatment harm.

Case: Vasomotor symptoms with an intact uterus

CLINICAL VIGNETTE

A 53-year-old with disruptive hot flashes is considering systemic menopausal hormone therapy. She has an intact uterus.

Which medication-design feature follows directly from uterine status?

SOURCE-BASED DISCUSSION

- A progestogen is ordinarily paired with estrogen.
- The rationale is endometrial protection from prolonged estrogenic stimulation.
- Vascular and breast risk require independent assessment.

Case: Symptoms after hysterectomy

CLINICAL VIGNETTE

A 52-year-old, previously treated by hysterectomy, seeks relief from menopausal vasomotor symptoms.

How does the absence of the uterus change regimen logic?

SOURCE-BASED DISCUSSION

- Estrogen-only therapy after hysterectomy.
- Removal of uterine risk does not eliminate breast or vascular questions.
- Age, route, duration, and baseline risk still matter.

Case: Inherited thrombophilia

CLINICAL VIGNETTE

A 56-year-old with vasomotor symptoms has a known factor V Leiden variant and is planning an extended period of immobilization.

What risk interaction is most important?

SOURCE-BASED DISCUSSION

- Inherited thrombophilia and immobilization both predispose to venous thrombosis.
- Systemic estrogen exposure adds a treatment-related risk concern.
- The scenario argues against treating age alone as sufficient risk assessment.

Case: MHT initiation at older age

CLINICAL VIGNETTE

A 68-year-old with no vasomotor complaints asks for MHT to prevent myocardial infarction and cognitive decline.

Does the supplied Robbins evidence support this goal?

SOURCE-BASED DISCUSSION

- No: MHT is not recommended for CVD or dementia prevention.
- Starting after 60 is associated with increased CHD and other vascular risk.
- Therapeutic goals must be separated from unproven preventive claims.

Case: Osteoporosis as the primary concern

CLINICAL VIGNETTE

A 58-year-old asks whether MHT is the preferred universal therapy to prevent fragility fractures.

What is the clinicopathologic trade-off?

SOURCE-BASED DISCUSSION

- Estrogen can reduce resorption and WHI reported fewer fractures.
- VTE and stroke limit indiscriminate estrogen treatment.
- Selective use and other bone-directed approaches.

Common misinterpretations and corrections

Misinterpretation	Source-consistent correction
“WHI showed MHT has no benefits.”	Fractures decreased; several major adverse events increased.
“All preparations have identical risks.”	Regimen, age, duration, dose, and route matter.
“Starting early prevents heart disease.”	Possible timing effects do not justify CVD prevention.
“Transdermal estrogen cannot cause VTE.”	Risk appears lower, not absent.
“Uterine status is irrelevant.”	Estrogen-alone therapy is reserved for hysterectomy in Robbins.

Five durable principles

- Treat menopausal symptoms—not an assumed cardiovascular or cognitive prevention benefit.
- Protect the intact endometrium from unopposed estrogenic exposure.
- Balance fracture reduction against breast, thrombotic, and stroke outcomes.
- Specify regimen, initiation age, baseline risk, duration, and route.
- Reassess rather than treating hormone exposure as a permanent default.

Source foundation and evidence boundaries

PRIMARY TEXTBOOK AND CROSS-CHAPTER CONTEXT

- Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026).
- Primary teaching section: Environmental and Nutritional Diseases — Menopausal Hormone Therapy.
- Integrated parent context: adverse drug reactions; cross-chapter biology of endometrial hyperplasia, thrombosis, and osteoporosis.
- The chapter PDF was not supplied; source statements were checked against the available extracted Robbins Markdown.
- No current external clinical guideline or independent WHI paper was used to alter the textbook's recommendations.